T. Rowe Price Associates’s Aquestive Therapeutics AQST Stock Holding History

T. Rowe Price Associates’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$374K	Buy	89,848 +17,332	+24%	+$72.9K	﹤0.01%	2756
2026 Q1	$301K	Buy	72,516 +16,565	+30%	+$67.2K	﹤0.01%	2680
2025 Q4	$362K	Buy	55,951 +10,865	+24%	+$67.7K	﹤0.01%	2551
2025 Q3	$253K	Buy	45,086 +2,144	+5%	+$9.27K	﹤0.01%	2690
2025 Q2	$143K	Buy	42,942 +10,848	+34%	+$31.1K	﹤0.01%	2815
2025 Q1	$94K	Buy	32,094 +4,425	+16%	+$13.4K	﹤0.01%	2830
2024 Q4	$99K	Buy	27,669 +3,821	+16%	+$17.6K	﹤0.01%	2831
2024 Q3	$119K	Hold	23,848	–	–	﹤0.01%	2787
2024 Q2	$0	Buy	+23,848	New	+$79.7K	﹤0.01%	2926

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

T. Rowe Price Associates's AQST Position: Q2 2026 in Review

T. Rowe Price Associates increased its Aquestive Therapeutics (AQST) stake by 24% in Q2 2026, buying an estimated $72.9K and bringing the position to 89,848 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #2756.

T. Rowe Price Associates first reported a position in AQST in Q2 2024 and has held it in 9 quarters since. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

T. Rowe Price Associates held 89,848 shares of Aquestive Therapeutics worth $374K as of Q2 2026.
T. Rowe Price Associates bought 17,332 Aquestive Therapeutics shares in Q2 2026, an estimated $72.9K.
Aquestive Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2756 holding.
T. Rowe Price Associates first reported a position in Aquestive Therapeutics in Q2 2024 and has held it in 9 quarters since.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.